1-(吡啶-4-基)哌啶-4-醇 | 130658-65-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(吡啶-4-基)哌啶-4-醇
• 英文名称: 1-(pyridin-4-yl)-4-hydroxypiperidine
• 英文别名: 1-(pyridin-4-yl)-4-piperidinol；1-(pyridin-4-yl)piperidin-4-ol；1-(4-Pyridyl)-4-piperidinol；1-(4-pyridyl)-4-hydroxypiperidine；4-hydroxy-1-(pyridin-4-yl)piperidine；4-(4-hydroxypiperidin-1-yl)pyridine；4-hydroxy-1-(4-pyridyl)piperidine；1-(4-pyridyl)-4-piperidin-1-ol；1-(4-pyridyl)piperidin-4-ol；1-pyridin-4-ylpiperidin-4-ol
• CAS: 130658-65-0
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD08437501
• 分子量: 178.234
• InChiKey: DMQVSUISDOVWEW-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162°C
• 沸点：
  340.7±32.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(吡啶-4-基)哌啶-4-醇 在 邻苯二甲酸亚胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 2-[1-(4-pyridyl)piperidin-4-ylaminocarbonyl]amino-nitrobenzene
  参考文献：
  名称：

  Non-Amidine-Containing 1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa with Potent Anticoagulant and Antithrombotic Activity

  摘要：

  DOI：

  10.1021/jm990625b
• 作为产物：
  描述：

  4-羟基哌啶 以 甲醇 为溶剂， 生成 1-(吡啶-4-基)哌啶-4-醇
  参考文献：
  名称：

  Heterocyclic compounds useful as pharmaceutical agents

  摘要：

  式(I)的化合物 其中所有变量在描述中定义，并且它们的盐抑制酶氧化甾二烯环化酶，在治疗高胆固醇血症和作为抗真菌剂方面具有用处。还描述了它们的制备过程以及它们在医学上的用途。

  公开号：

  US06313127B1

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US06313122B1

  公开（公告）日：2001-11-06

  This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  这项申请涉及到式(I)的化合物，该化合物的药用盐或其前药，如本文所定义，以及其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备方法和中间体。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20030207882A1

  公开（公告）日：2003-11-06

  Compounds of formula (I), wherein G 1 is CH or N; G 2 is CH or N; R 1 is a variety of optional substituents, L 1 is (1-4C)alkylene; T 1 is CH or N; R 2 and R 3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X 1 and X 2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described. 1

  式（I）的化合物，其中G1为CH或N；G2为CH或N；R1为各种可选取代基，L1为（1-4C）烷基；T1为CH或N；R2和R3独立地为氢或（1-4C）烷基或连接成环；X1和X2代表各种连接基团；Ar为苯基或特定杂环芳基，Q代表各种芳香或杂环芳基系统，及其药学上可接受的盐被描述为有用的抗血栓和抗凝血剂，并且是选择性的凝血因子Xa抑制剂。还描述了其制备方法和含有它们的药物组合物。